FREMONT, Calif. and LUXEMBOURG, Dec. 14, 2015 /PRNewswire/ -- WaferGen Bio-systems (NASDAQ:
The ICELL8 Single-Cell System is a revolutionary platform which can isolate thousands of single cells and process specific cells of interest for downstream analysis using Next Generation Sequencing. The system was developed in collaboration with several leading medical research centers under an early access program, including the Karolinska Institutet in Sweden. Recently, WaferGen presented results generated by the ICELL8 Single-Cell System at the Single Cell Genomics Conference in Utrecht, Netherlands, demonstrating that the system is capable of isolating and selecting over 13,000 single cells in less than 8 hours using its automated dispensing and image analysis software.
"The Luxembourg Institute of Health continuously strives to provide the most innovative technologies to advance medical research and improve patient health care," said Dr. Jean-Claude Schmit, General Director, LIH. "Collaborating with leading biotechnology companies, such as WaferGen, is one important avenue to enhance our scientific and academic programs, and we are pleased to be providing both Luxembourg and European researchers access to this novel single-cell analysis system."
In 2011, WaferGen formed a wholly-owned subsidiary in Luxembourg to establish a presence for the Company's marketing and research activities in Europe. The Luxembourg Ministry of Finance provided assistance to support the establishment of the WaferGen subsidiary. Earlier in 2015, the Company established...